| Name | Title | Contact Details |
|---|
Molina Healthcare of Michigan is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OnPoint Medical Diagnosis is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Minneapolis, MN. To find more information about OnPoint Medical Diagnosis, please visit www.onpointmd.com
Heyday is a people-first skincare company, bringing together human touch, expertise, and data to personalize and empower people to take care of their skin. We opened our first retail location in 2015 – taking the facial and indulgence out of the spa, elevating the estheticians as the experts they are, and removing the overwhelm out of building an at-home skincare routine. Today, we have 9 locations in New York, Los Angeles, and Philadelphia. We`ve performed 225,000 facials, collected data on skincare conditions, preferences, and purchases, and become an employer of choice for a world-class team of estheticians we call Heyday Skin Therapists. Our next chapter is to take these ingredients and create unparalleled personalization and guidance across content, communities, recommendations, and services in both our physical stores and our e-commerce experience. `Heyday` means a period of your life when you`re feeling at your best. Above all, we exist to help people achieve their `heyday` – to show up in the world as their best selves, every day. We start with the skin you`re in.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
Eagle Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing injectable products, primarily in the critical care and oncology areas, using the 505(b)(2) regulatory pathway.